Belantamab Mafodotin Moves Into Lenalidomide-Refractory Myeloma in Updated NCCN Guidelines
The NCCN updated its guidelines to include GSK's belantamab mafodotin (Blenrep) plus bortezomib and dexamethasone as a category 1 recommendation for lenalidomide-refractory multiple myeloma. The update also includes two other belantamab triplets under 'Useful in Certain Circumstances' for patients with 3 or more prior therapies. The changes follow the drug's FDA approval in October 2025 and reflect its efficacy in clinical trials.
How this was made
The 30-second read
Why it matters
The inclusion of belantamab mafodotin‑based regimens expands treatment options for lenalidomide‑refractory patients, potentially increasing sales for GSK and its partners.
Market read
Guideline upgrade creates a near‑term catalyst for GSK and partner stocks, while highlighting safety considerations that may temper enthusiasm.
What to watch
Ocular toxicity of belantamab mafodotin could limit real‑world uptake despite the NCCN endorsement.
Background
The NCCN guideline is a key reference for oncologists; changes can quickly affect prescribing patterns and market expectations for related drugs.
Ticker impact
NCCN added GSK's belantamab mafodotin (Blenrep) plus bortezomib and dexamethasone as a Category 1 recommendation for lenalidomide‑refractory multiple myeloma.
likely upside as investors price in expanded indication.
First‑time NCCN Category 1 recommendation expands patient pool beyond FDA label, creating new sales opportunity.
Takeda's bortezomib (Velcade) is part of the newly recommended BVd regimen for lenalidomide‑refractory myeloma.
potential modest upside from higher usage forecasts.
Guideline endorsement may drive off‑label use and boost sales, but impact depends on reimbursement.
Bristol Myers Squibb's pomalidomide (Pomalyst) is paired with belantamab mafodotin in the BPd triplet listed as useful in certain circumstances.
slight upside as combination may generate incremental revenue.
BPd lacks FDA approval; market impact limited until regulatory clearance.
Amgen's carfilzomib (Kyprolis) appears in the BKd regimen noted as useful for heavily pre‑treated patients.
minor upside if clinicians adopt the regimen.
Regimen is not FDA‑approved; adoption uncertain.
Johnson & Johnson's talquetamab‑tgvs (Talvey) is mentioned as a bridge therapy to BCMA‑directed CAR‑T in the NCCN update.
no immediate price move expected.
Mention only as a potential bridge; no new data or approval disclosed.
Market effects
Oncology drug pipelines may see heightened investor interest as guideline changes expand eligible patient populations.
U.S. and European biotech stocks could experience modest gains from broader myeloma treatment options.
Limited to companies with approved or pipeline BCMA‑targeted therapies; broader market impact minimal.
Counterpoint
Guideline upgrades may not translate into sales if payers restrict reimbursement or if safety concerns persist.
Key entities
- organizationNational Comprehensive Cancer Network
Publishes clinical practice guidelines for cancer treatment.
- drugBelantamab mafodotin (Blenrep)
Antibody‑drug conjugate targeting BCMA, now recommended by NCCN.
